Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Common Equity (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Common Equity data on record, last reported at $83.9 million in Q3 2025.

  • For Q3 2025, Common Equity rose 22.86% year-over-year to $83.9 million; the TTM value through Sep 2025 reached $83.9 million, up 22.86%, while the annual FY2024 figure was $145.5 million, 543.6% up from the prior year.
  • Common Equity reached $83.9 million in Q3 2025 per CAPR's latest filing, down from $105.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $145.5 million in Q4 2024 and bottomed at -$1.8 million in Q3 2023.
  • Average Common Equity over 5 years is $42.0 million, with a median of $24.6 million recorded in 2022.
  • Peak YoY movement for Common Equity: tumbled 111.59% in 2023, then surged 3918.69% in 2024.
  • A 5-year view of Common Equity shows it stood at $31.4 million in 2021, then plummeted by 62.43% to $11.8 million in 2022, then surged by 91.76% to $22.6 million in 2023, then surged by 543.6% to $145.5 million in 2024, then crashed by 42.34% to $83.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $83.9 million in Q3 2025, $105.0 million in Q2 2025, and $127.6 million in Q1 2025.